Detalles de la búsqueda
1.
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
N Engl J Med
; 384(16): 1491-1502, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33631065
2.
Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.
J Infect Dis
; 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37972260
3.
Pbx4 limits heart size and fosters arch artery formation by partitioning second heart field progenitors and restricting proliferation.
Development
; 147(5)2020 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32094112
4.
CD4+ T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-α/Tumor Necrosis Factor Receptor 1-Dependent.
Am J Respir Crit Care Med
; 205(12): 1403-1418, 2022 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35348444
5.
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).
Clin Infect Dis
; 75(1): e630-e644, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35179197
6.
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA
; 327(13): 1247-1259, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35315874
7.
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA
; 326(17): 1690-1702, 2021 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34606578
8.
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
JAMA
; 324(13): 1317-1329, 2020 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32876697
9.
The Epidemiology of Extremity Threat and Amputation after Vasopressor-Dependent Sepsis.
Ann Am Thorac Soc
; 19(4): 625-632, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34644242
10.
A learning health system approach to the COVID-19 pandemic: System-wide changes in clinical practice and 30-day mortality among hospitalized patients.
Learn Health Syst
; 6(3): e10304, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35860323
11.
Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days.
Contemp Clin Trials
; 113: 106652, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34896293
12.
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
JAMA Netw Open
; 5(4): e226920, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35412625
13.
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
JAMA Netw Open
; 5(7): e2220957, 2022 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35834252
14.
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
Contemp Clin Trials
; 119: 106822, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35697146
15.
Perceptions of Hyperoxemia and Conservative Oxygen Therapy in the Management of Acute Respiratory Failure.
Ann Am Thorac Soc
; 18(8): 1369-1379, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33332994
16.
Rationale and design of the Prone Position and Respiratory Outcomes in Non-intubated COVID-19 PatiEnts: The "PRONE" Study.
Contemp Clin Trials
; 109: 106541, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34400361
17.
Enhancing Implementation of Complex Critical Care Interventions through Interprofessional Education.
ATS Sch
; 2(3): 370-385, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34667987
18.
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Open Forum Infect Dis
; 8(7): ofab254, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34250192
19.
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
Trials
; 22(1): 363, 2021 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34034784
20.
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Intensive Care Med
; 47(8): 867-886, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34251506
Resultados
1 -
20
de 20
1
Próxima >
>>